Cargando…

Risk of Malignancy and Biologic Therapy in Rheumatic Inflammatory Diseases: A Single-center Experience

OBJECTIVES: Biologic disease modifying anti-rheumatic drugs (bDMARDs) have significantly improved the care of patients with rheumatic muscle-skeletal disorders (RMDs). Considering their immunosuppressive action, a theoretical increase of malignancy risk has been a major concern in the last few decad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cometi, Laura, Bruni, Cosimo, Passavanti, Saverio, Tofani, Lorenzo, Bartoli, Francesca, Fiori, Ginevra, Nacci, Francesca, Lepri, Gemma, Orlandi, Martina, Melchiorre, Daniela, Antonuzzo, Lorenzo, Matucci-Cerinic, Marco, Moggi-Pignone, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2020
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524767/ https://www.ncbi.nlm.nih.gov/pubmed/36465081 http://dx.doi.org/10.2478/rir-2020-0001

Ejemplares similares

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
por: Cometi, Laura, et al.
Publicado: (2020)

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience
por: Tesei, Giulia, et al.
Publicado: (2021)

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
por: Bruni, Cosimo, et al.
Publicado: (2021)

The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life
por: El Aoufy, Khadija, et al.
Publicado: (2021)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
por: Bruni, Cosimo, et al.
Publicado: (2020)

Oral Lactobacillus Species in Systemic Sclerosis
por: Melchiorre, Daniela, et al.
Publicado: (2021)

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress
por: Orlandi, Martina, et al.
Publicado: (2020)

The Emerging Challenge of Pain in Systemic Sclerosis: Similarity to the Pain Experience Reported by Sjőgren’s Syndrome Patients
por: De Luca, Rossella, et al.
Publicado: (2021)

Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis
por: Bruni, Cosimo, et al.
Publicado: (2022)

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
por: Orlandi, Martina, et al.
Publicado: (2022)

Systemic Sclerosis Association with Malignancy
por: Lepri, Gemma, et al.
Publicado: (2022)

Menstruation-Related Disorders—Dysmenorrhea and Heavy Bleeding—as Significant Epiphenomena in Women With Rheumatic Diseases
por: Orlandi, Martina, et al.
Publicado: (2022)

Safety and efficacy of biological therapy with TNF-inhibitors and non TNF-inhibitors in a cohort of young adults affected by juvenile idiopathic arthritis (JIA): data from a single centre experience
por: Lorenzo, Ceri, et al.
Publicado: (2011)

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?
por: Matucci-Cerinic, Marco, et al.
Publicado: (2017)

Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data
por: Fiorentini, Elisa, et al.
Publicado: (2022)

Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates
por: Caforio, Alida Linda Patrizia, et al.
Publicado: (2021)

The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review
por: Peretti, Silvia, et al.
Publicado: (2022)

Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis–Interstitial Lung Disease: A Systematic Review
por: Landini, Nicholas, et al.
Publicado: (2022)

Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis
por: Mazzotta, Celestina, et al.
Publicado: (2015)

Rehabilitation of the face and temporomandibular joint in systemic sclerosis
por: Maddali Bongi, Susanna, et al.
Publicado: (2021)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

Transition care: the link between pediatric rheumatology and adult rheumatology. Data from the experience of the young adult rheumatology ambulatory of Florence
por: Falcini, Fernanda, et al.
Publicado: (2014)

From pandas to pans: a nosographic entity in evolution throughout a descriptive analysis of a cohort of 103 italian children and adolescents
por: Falcini, Fernanda, et al.
Publicado: (2014)

Pathophysiology of Hemophilic Arthropathy
por: Melchiorre, Daniela, et al.
Publicado: (2017)

Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells
por: Mazzotta, Celestina, et al.
Publicado: (2017)

The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review
por: Bonomi, Francesco, et al.
Publicado: (2022)

Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability
por: Bandinelli, Francesca, et al.
Publicado: (2016)

Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
por: Bargagli, Elena, et al.
Publicado: (2019)

Temporomandibular joint involvement (TMJ), a silent disease with severe alterations in young adulthood patients affected by juvenile idiophatic arthritis (JIA)
por: Fernanda, Falcini, et al.
Publicado: (2011)

The waterpolo shoulder paradigm: results of ultrasound surveillance at poolside
por: Galluccio, Felice, et al.
Publicado: (2017)

Comparison of three treatment protocols with intra-articular low or intermediate molecular weight hyaluronic acid in early symptomatic knee osteoarthritis
por: Galluccio, Felice, et al.
Publicado: (2021)

Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide
por: Borghini, Annalisa, et al.
Publicado: (2015)

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
por: Denton, Christopher P, et al.
Publicado: (2020)

Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
por: Paderi, Agnese, et al.
Publicado: (2021)

Seronegative enthesoarthritis as the first presentation of the atrial myxoma
por: Francesco, Bonomi, et al.
Publicado: (2023)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

PReS-FINAL-2252: Descriptive analysis of pediatric autoimmune neuropsychiatric disorder associated with streptococcus infection (PANDAS) in a cohort of 65 Italian patients
por: Falcini, F, et al.
Publicado: (2013)

PReS-FINAL-2315: Severe cutaneous vasculitis in two patients with juvenile idiopathic arthritis and biologic therapy
por: Falcini, F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4k9v8ug74obgpfghdigsji0hpg